{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:54:06Z","timestamp":1763016846068,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":2565,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1016\/j.bbmt.2008.01.008","type":"journal-article","created":{"date-parts":[[2008,3,14]],"date-time":"2008-03-14T10:05:35Z","timestamp":1205489135000},"page":"418-425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":110,"title":["Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non-Hodgkin Lymphoma: Importance of Histology for Outcome"],"prefix":"10.1016","volume":"14","author":[{"given":"Philippe","family":"Armand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haesook T.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent T.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey S.","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Koreth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph H.","family":"Antin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann S.","family":"LaCasce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric D.","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George P.","family":"Canellos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold S.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Soiffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin P.","family":"Alyea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2008.01.008_bib1","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.3324\/haematol.11185","article-title":"Allogeneic transplantation in lymphoma: current status","volume":"92","author":"Schmitz","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2008.01.008_bib2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bmt.1703891","article-title":"An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation","volume":"31","author":"Peniket","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2008.01.008_bib3","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"van Besien","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.01.008_bib4","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2003.08.054","volume":"21","author":"Bierman","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2008.01.008_bib5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood.V106.11.44.44","article-title":"Longer follow-up confirms a low relapse rate after non-myeloablative allogeneic transplantation (NMT) for non-Hodgkin's lymphoma (NHL), including patients with PET or gallium-avid disease","volume":"106","author":"Khouri","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.01.008_bib6","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.bbmt.2006.06.004","article-title":"Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia","volume":"12","author":"Brown","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2008.01.008_bib7","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2008.01.008_bib8","first-page":"825","article-title":"1994 Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2008.01.008_bib9","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"10.1016\/j.bbmt.2008.01.008_bib10","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2008.01.008_bib11","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.bmt.1704942","article-title":"Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen","volume":"35","author":"Anderlini","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2008.01.008_bib12","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.1993.11.12.2342","article-title":"Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience","volume":"11","author":"Anderson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2008.01.008_bib13","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.1996.14.4.1291","article-title":"Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation","volume":"14","author":"Milpied","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2008.01.008_bib14","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1200\/JCO.2001.19.23.4314","article-title":"Long-term results of blood and marrow transplantation for Hodgkin's lymphoma","volume":"19","author":"Akpek","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2008.01.008_bib15","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2004-03-1105","article-title":"Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma","volume":"104","author":"Morris","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.01.008_bib16","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1182\/blood.V106.11.1130.1130","article-title":"Allogeneic hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning for relapsed or refractory follicular lymphoma. (ASH Annual Meeting Abstracts)","volume":"106","author":"Maris","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.01.008_bib17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.blre.2006.01.001","article-title":"The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma","volume":"20","author":"Van Besien","year":"2006","journal-title":"Blood Rev"},{"key":"10.1016\/j.bbmt.2008.01.008_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/sj.leu.2404822","article-title":"Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome","author":"Corradini","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2008.01.008_bib19","article-title":"Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma","author":"Rezvani","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2008.01.008_bib20","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1182\/blood.V106.11.1143.1143","article-title":"Allogeneic hematopoietic cell transplantation (HCT) with nonmyeloablative conditioning after failed myeloablative HCT: factors affecting outcomes. (ASH Annual Meeting Abstracts)","volume":"106","author":"Baron","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.01.008_bib21","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","article-title":"Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation","volume":"100","author":"Robinson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.01.008_bib22","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1182\/blood-2003-05-1406","article-title":"BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients","volume":"103","author":"Faulkner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.01.008_bib23","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2141.2005.05755.x","article-title":"Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma","volume":"131","author":"Doocey","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2008.01.008_bib24","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/sj.bmt.1705080","article-title":"Stem cell transplantation for mantle cell lymphoma: if, when and how?","volume":"36","author":"Kiss","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2008.01.008_bib25","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1182\/blood-2004-06-2275","article-title":"Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma","volume":"104","author":"Maris","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.01.008_bib26","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1182\/blood.V104.11.2260.2260","article-title":"Reduced intensity allogeneic stem cell transplantation for mantle cell lymphoma is associated with substantial late transplant related mortality and a poor outcome in patients with chemoresistant disease. (ASH Annual Meeting Abstracts)","volume":"104","author":"Robinson","year":"2004","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879108000517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879108000517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:30:53Z","timestamp":1761057053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879108000517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["S1083879108000517"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2008.01.008","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2008,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non-Hodgkin Lymphoma: Importance of Histology for Outcome","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2008.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}